BIOENGINEERING IS NOW PART OF MORIMATSU GROUP

We are pleased to announce that Bioengineering AG (hereinafter referred to as "Bioengineering") has officially joined the Morimatsu Group. This integration represents a significant milestone in Morimatsu LifeSciences global strategy and substantially enhances Morimatsu’s capabilities in the biopharmaceutical and synthetic biology sectors. By strengthening technological advantages and expanding market coverage in core equipment such as bioreactors and fermentation system, this acquisition will accelerate Morimatsu’s penetration and competitiveness in global high-end markets.

Bioengineering will synergize with other brands within the Group to extend Morimatsu’s upstream bioprocessing value chain, offering customers a broader portfolio of solutions and delivering enhanced value to downstream industries. With the joining of Bioengineering, the Morimatsu Group now boasts two renowned European brands. Pharmadule Morimatsu AB (Sweden), has specialized in modular facilities. The acquisition of Bioengineering will further strengthen Morimatsu’s competitiveness in the high-end bioprocessing market, enhancing its technological leadership and market presence in bioreactors and fermentation systems, while upgrade the“global R&D and production diversification” strategy. In the future, Morimatsu will significantly improve responsiveness, local service capabilities, and technical support efficiency in Europe and other key international markets. The global supply chain synergies will become increasingly prominent, ultimately strengthening the multi-brand portfolio and building a more resilient and diversified competitive advantage worldwide. The Morimatsu Group has established cross-industry collaborations with numerous Fortune 500 companies, including 80% of the world’s top 20 pharmaceutical companies, leading regional and sector-specific clients. Bioengineering is a globally recognized, R&D-driven manufacturer renowned for pioneering high-end bioreactor and cultivation systems. With over half a century of technological expertise and proven market performance, it stands as an industry benchmark, with products and services highly regarded across global high-end markets. The collaboration between the two entities will generate a cascading synergistic effect in the field of bioreactors and cultivation systems. Morimatsu’s advanced, efficient, and large-scale production bases will integrate deeply with Bioengineering’s technological strengths to offer global customers more flexible and customized solutions. Together, they will leverage a broader solution portfolio, a more premium value proposition, and enhanced service systems to realize synergies and explore new market opportunities. The two brands will jointly sustain industry leadership and achieve a mutually reinforcing development model, enabling shared growth in the global high-end bioprocessing industry.